Mayoly in the news

Mayoly has relocated the production of colchicine, an essential gout medication, to France with a 3 million euro investment, despite higher costs and an anticipated sales start in mid-2027.

Mayoly is relocating colchicine production from Eastern Europe to Auxerre, France, partnering with Galien.

Mayoly relocated the production of colchicine, an essential gout medication, to France with significant investment, despite higher costs, to ensure national supply and reduce foreign dependency.

Mayoly pharmaceutical group is moving the production of colchicine from Eastern Europe to Auxerre, with partner Galien.

Mayoly is investing 2.5 million euros to reshore the production of the essential gout medication colchicine to a new manufacturing line in Burgundy by 2027.

Mayoly is investing 2.5 million euros to relocate the production of the essential medicine colchicine to a specialized factory in Auxerre to secure supply for 600,000 patients.

Mayoly and Galien have launched a new production line in Auxerre to manufacture three million boxes of Colchicine annually, reshoring production from Eastern Europe to France.

Pharmaceutical group Mayoly is moving its colchicine production from Eastern Europe to a facility in Auxerre, France.

Mayoly relocated colchicine production to France through a 3 million euro investment despite a doubling of manufacturing costs.

Mayoly is investing 2.5 million euros to reshore the production of the essential gout drug Colchicine to France to secure domestic supply.

Mayoly has inaugurated a new production line for the strategic drug Colchicine in Auxerre to repatriate manufacturing to France.

Mayoly is relocating the manufacturing of the critical gout medicine colchicine from Romania to France via a multi-million euro investment supported by state funding.

Mayoly is investing 2.5 million euros to relocate the manufacturing of the essential drug Colchicine to a partner site in Auxerre, France.

French laboratory Mayoly has opened a new production line to relocate the manufacturing of the essential gout medication colchicine to France.

Mayoly is investing 2.5 million euros to reshore the production of essential gout medication to France through a partnership with the subcontractor Galien.

Mayoly is investing 2.5 million euros to relocate the production of its essential anti-inflammatory drug colchicine from Romania to Auxerre, France.

Mayoly and partner Galien invested 3 million euros to relocate colchicine production and packaging to a facility in Auxerre, France.

Laboratoires Mayoly Spindler SAS has 965 employees and is a French, independent pharmaceutical company specializing in gastroenterology, rheumatology, ENT, and dermo-cosmetics.

Mayoly's General Manager for France discusses the balance between political health policies and pharmaceutical business operations.

Mayoly has strategically focused on the Chinese market for digestive health, expanding its presence, production, and distribution, while positioning China as a key driver for global growth and innovation.